ArticleAnnals of intensive care2015
Mechanisms of antimicrobial resistance in Gram-negative bacilli.
Article in Annals of intensive care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 3 syntheses or guidelines pooled it, 483 citations in OpenAlex.
- What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.The Journal of antimicrobial chemotherapy · 2024Pooled it
- Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Molecular epidemiology of fluoroquinolone resistant Salmonella in Africa: A systematic review and meta-analysis.PloS one · 2018Pooled it
- Management of Ventilator-Associated Pneumonia Caused byMedicina (Kaunas, Lithuania) · 2024Trial
- Trial
- Fish gut-water interface as a hotspot for the dissemination of antibiotic resistance genes across natural and aquaculture systems.Current research in microbial sciences · 2026Article
- Development and comparative evaluation of in vitro, ex vivo, and in vivo models for the assessment of broad-spectrum topical antimicrobial efficacy.Scientific reports · 2026Article
- Non canonical perspectives on AmpR mediated ampC expression in Gram negative bacteria, with particular emphasis on the potential regulatory purview of FtsZ.World journal of microbiology & biotechnology · 2026Review
- Trends in Enterobacteriaceae Resistance Patterns: A Nine-Year Retrospective Study From North Lebanon.Health science reports · 2026Article
- Dissemination of antimicrobial resistance in surface waters: surveillance of enterococci and coliform bacteria in Slovakia.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Risk factors associated with rectal carriage of extended spectrum beta-lactamases producing Enterobacterales among inpatients at a tertiary hospital in Northern Nigeria: A cross-sectional study.Scientific reports · 2026Article
- Epidemiology and Molecular Profiles of ESBL-ProducingMicroorganisms · 2026Article
- Fluoroquinolone-Induced Metabolic Dysregulation and Oxidative Stress Orchestrate Bacterial Demise.Microorganisms · 2026Article
- Safety Profiles of Polymyxins, Aminoglycosides, and Imipenem/Cilastatin/Relebactam (IMI/REL) in the Treatment of Gram-Negative Infections: A Literature Review.Antibiotics (Basel, Switzerland) · 2026Review
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Silver Nanoparticles as Antibacterials: Synthesis, Characterization, and Molecular Simulations Against β-Lactamase-Producing Enterobacter and Salmonella spp.Molecular biotechnology · 2026Article
- A One Health comparative genomic assessment of antimicrobial-resistantApplied and environmental microbiology · 2026Article
- Early-Life β-Lactam Exposure and the Developing Microbiome: Clinical Relevance and Controversies.Microorganisms · 2026Review
- Evolution of Antimicrobial Resistance inMicroorganisms · 2026Review
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of multidrug resistance in Gram-negative bacilli (GNB) now represents a daily issue for the management of antimicrobial therapy in intensive care unit (ICU) patients. In Enterobacteriaceae, the dramatic increase in the rates of resistance to third-generation cephalosporins mainly results from the spread of plasmid-borne extended-spectrum beta-lactamase (ESBL), especially those belonging to the CTX-M family. The efficacy of beta-lactam/beta-lactamase inhibitor associations for severe infections due to ESBL-producing Enterobacteriaceae has not been adequately evaluated in critically ill patients, and carbapenems still stands as the first-line choice in this situation. However, carbapenemase-producing strains have emerged worldwide over the past decade. VIM- and NDM-type metallo-beta-lactamases, OXA-48 and KPC appear as the most successful enzymes and may threaten the efficacy of carbapenems in the near future. ESBL- and carbapenemase-encoding plasmids frequently bear resistance determinants for other antimicrobial classes, including aminoglycosides (aminoglycoside-modifying enzymes or 16S rRNA methylases) and fluoroquinolones (Qnr, AAC(6')-Ib-cr or efflux pumps), a key feature that fosters the spread of multidrug resistance in Enterobacteriaceae. In non-fermenting GNB such as Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia, multidrug resistance may emerge following the sole occurrence of sequential chromosomal mutations, which may lead to the overproduction of intrinsic beta-lactamases, hyper-expression of efflux pumps, target modifications and permeability alterations. P. aeruginosa and A. baumannii also have the ability to acquire mobile genetic elements encoding resistance determinants, including carbapenemases. Available options for the treatment of ICU-acquired infections due to carbapenem-resistant GNB are currently scarce, and recent reports emphasizing the spread of colistin resistance in environments with high volume of polymyxins use elicit major concern.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.